Navigation Links
Clinical Next Generation Sequencing Market: NGS Diagnostic 2018 Forecast in New Industry Research Report at ReportsnReports.com
Date:7/16/2013

Dallas. Texas (PRWEB) July 16, 2013

“Next Generation Sequencing: Emerging Clinical Applications and Global Markets” Report Highlights -
This report provides:

  •     An overview of the global market for next-generation sequencing and its emerging clinical applications
  •     Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
  •     Examination of the sequencing industry structure for the key market segments, as well as strategic alliances and acquisitions, as well as evaluations of sequencing patents
  •     Discussion of the strategies of the main companies in the market
  •     Comprehensive company profiles of major players in the segment.

Report Scope

Study Goals and Objectives
The goal of this study is to provide an in-depth analysis of the clinical next generation sequencing (NGS) industry (http://www.reportsnreports.com/reports/265829-next-generation-sequencing-emerging-clinical-applications-and-global-markets.html) , an emerging industry with enormous market potential. The approach of analyzing the industry is taken in terms of workflow (e.g., sequencers, sequence capture, informatics) and key indications where NGS diagnostics will have market share by 2018.

This report examines the markets for NGS diagnostics for the years 2012, 2013 and 2018.

The global NGS diagnostic markets are characterized and quantified by disease indication, test complexity, test purpose and geography.

Market segments that provide exciting growth opportunities include cancer, rare genetic diseases and prenatal screening.

The report provides a comprehensive discussion of NGS technologies, clinical applications, industry structure, important clinical sequencing initiatives, global markets, patent status and companies. The report is designed to aid companies in their strategic planning efforts for clinical genetic testing.

Reasons for Doing the Study
The Human Genome Project (HGP) moved DNA sequencing technology to the forefront of life science research as a genetic analysis tool. The HGP relied heavily on Sanger sequencing by capillary electrophoresis to decipher the DNA sequence of the bases in the human genome.

The HGP led to significant improvements in the efficiency and costs of DNA sequencing. During this time period, the sequencing industry consolidated, resulting in one dominant company, Applied Biosystems (now Life Technologies).

Beginning in 2005, the launch of next generation sequencing technologies radically changed the structure of the industry and opened up exciting new market applications. The costs of sequencing have rapidly reduced to the point where it is now feasible for complex NGS tests to be priced in the range of other multiplex genetic tests.

As a result, opportunities emerged in clinical applications that are currently reaching fruition. The NGS clinical market is still relatively young and emerging, yet it holds great commercial promise.

Clinical value has been shown for many applications, and several launched tests are having good commercial success. This shows that both patients and physicians are recognizing the value of NGS tests. Several molecular genetic tests that have been successful on non-NGS formats will run on NGS platforms in the future.

At the same time, payors and insurance companies are beginning to provide coverage for these tests, further enhancing their commercial potential.

These technical and market factors are driving this market so that in 2013, it is timely to examine the clinical segment of the sequencing industry.

Buy a copy of report @ http://www.reportsnreports.com/purchase.aspx?name=265829. Alternatively can get DISCOUNT @ http://www.reportsnreports.com/contacts/discount.aspx?name=265829.

Scope and Format
The scope of the report includes clinical NGS technologies, applications, industries, initiatives, patents and companies. The markets for NGS-based diagnostics are given for the years 2012, 2013 and 2018.

This report reviews the main sequencing technologies and explains why genetic variation is important in clinical testing. It then discusses some of the top research initiatives that are contributing to clinical NGS applications. Market driving forces are also discussed.

The report examines the markets by test complexity, indication and test purpose. Test complexity refers to the multiplexing (e.g., the number of genes covered) and coverage (e.g., the extent to which the genome is covered) of the test. Examining the market by test complexity provides valuable insight into which products (e.g., sample preparation, NGS instrument, informatics) will be in demand in the future.

The report provides market data and forecasts for NGS diagnostics by specific applications, including those for cancer, rare diseases, common diseases, and pre- and post-natal screening.

Specific geographic markets are discussed, including North America, Europe, China, Japan and the rest of the world.

Market data covers the years 2012, 2013 and 2018.

Industry sectors analyzed include NGS instruments, target enrichment, informatics, clinical laboratories and the prenatal screening industry.

More than 110 companies in the clinical NGS industry are profiled in this report.

Explore more reports @ http://www.reportsnreports.com/market-research/biotechnology/.

About US:
ReportsnReports.com is an online market research reports (http://www.reportsnreports.com/) library of 200,000+ reports and in-depth studies of 5000+ micro markets. Our database includes reports by leading publishers from across the globe.

Read the full story at http://www.prweb.com/releases/clinical-next-generation/sequencing-ngs-market/prweb10931917.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. First targeted nanomedicine to enter human clinical studies
2. Clinical insight improves treatment with new lung cancer drug
3. Clinical news alert from the American Academy of Orthopaedic Surgeons
4. NYU Langone experts present research, clinical advances at neurosurgeons meeting
5. Kroenke honored for outstanding contributions in clinical research training
6. Awards celebrate clinical research that can improve health and alleviate suffering
7. Association for Psychological Science, SAGE launch Clinical Psychological Science
8. URMC clinical trial tests new regimen for hypertension
9. Analysis Finds Clinical Trials Often Small, of Poor Quality
10. Automated insulin dosage titration system demonstrates positive clinical study results
11. Clinical news alert: Journal of the American Academy of Orthopaedic Surgeons May highlights
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... In light of recent heavy flooding in ... of contaminated well water throughout the Houston area. , Heavy floodwaters have led to ... exposed to contaminants. Residents may not even be aware of the contamination of their ...
(Date:5/24/2016)... ... ... The Dream Builders Project, a 501(c)3 nonprofit organization based in Los Angeles, ... Mexico on Saturday, May 21st. The volunteers took the children out for the day ... 15 volunteers traveled from Los Angeles to Tijuana, Mexico for the day in the ...
(Date:5/24/2016)... (PRWEB) , ... May 24, 2016 , ... ... and tick-borne disease research and education, today announced that it has named Scott ... of the Bonnie J. Addario Lung Cancer Foundation (ALCF) in San Francisco, where ...
(Date:5/24/2016)... ... May 24, 2016 , ... PhysicianOne Urgent Care, advocators in helping ... bites and how to avoid being bitten this spring. , The official tick ... Ticks, small spider-like insects, are known for attaching themselves to their prey while they ...
(Date:5/24/2016)... ... May 24, 2016 , ... Applications ... multiplex immunoassays are widely used for cell and protein analysis. Keeping updated on ... quality and efficiency in these areas. , LabRoots introduces a new complementary ...
Breaking Medicine News(10 mins):
(Date:5/23/2016)... World Health Organization (WHO) expanded the Intended Use of the ... years, and above. Effective immediately, the PrePex device, manufactured by ... in the 14 priority countries in Southern and ... device to receive WHO Prequalification on 31 May 2013. ... The expanded use of PrePex for younger ages ...
(Date:5/23/2016)... 23, 2016 Gamida Cell, a ... of cancer and orphan genetic diseases, announced today it ... million from the Israel Innovation Authority (formerly the Office ... Economy and Industry. The mission of the Israel Innovation ... industries, including science and technology, while stimulating economic growth. ...
(Date:5/22/2016)... 2016 DS Biopharma (DS) ... anti-inflammatory compound DS102 in chronic obstructive pulmonary disease ... (NASH) patients. Recent DS preclinical data ... tissue and has bronchodilatory, anti-inflammatory and anti-fibrotic properties ... Company will publish further detail on these findings ...
Breaking Medicine Technology: